Previous evidence suggested the potential anti-cancer activity of luteolin and apigenin by downregulating the AR and AKT signaling in PCa cells (Gupta et al., 2002; Chiu and Lin, 2008; Kaur et al., 2008; Shukla et al., 2014). The gene discussed is AR; the disease is posterior cortical atrophy.